TrialClinical cancer research : an official journal of the American Association for Cancer Research2023

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Sophie Wildsmith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.